**CAPiTA Trials results – Community Acquired Pneumonia Immunisation Trial in Adults**

**Speaker:** Dr Marieka Bolkenbass, CAPiTA trial investigator Julius Centre for Health Sciences and Primary Care, the Netherlands

**Venue:** Room 305, Level 3, Samuels Building, UNSW upper campus, Randwick

**Date:** Wednesday 3 June 2015

**Time:** 12:00-1:00pm (light refreshment is provided)

**Enquiries:** Nina Mili n.mili@unsw.edu.au

Parking: Available on L5 of the parking station; enter via Gate 11 Botany St, Randwick


**ABSTRACT**

Dr Marieke Boleknabbas, a lead investigator, will present the results of the CAPiTA Trial (community acquired pneumonia immunisation trial in adults). Conjugate vaccines have shown to prevent pneumococcal disease in children, but efficacy in elderly has not been established yet. Pneumococcal disease, including pneumococcal pneumonia, is a major cause of disease worldwide, primarily affecting infants and the elderly. One of the largest vaccine efficacy trials ever conducted in adults, the primary objective of CAPiTA was to determine the efficacy of the 13-valent pneumococcal conjugate vaccine (13vPnC) in preventing a first episode of vaccine-type (VT) pneumococcal community-acquired pneumonia (CAP).

**BIOGRAPHY**

Marieka Bolkenbass (Hoorn, the Netherlands, 1976) studied Medical Biology and Medicine at the University of Amsterdam. In 2008 she started working on the CAPiTA trial as a PhD student at the department Epidemiology of Infectious Diseases of the Julius Centre, part of the University Medical Centre in Utrecht, and started her vocational training in Family Practice. The focus of her research is on effects of pneumococcal vaccination on lower respiratory tract infections in elderly in primary care. Since 2013 she works as a general practitioner in the Utrecht area, a job she combines with her research work.